208 related articles for article (PubMed ID: 18097939)
1. Dimeric DOTA-alpha-melanocyte-stimulating hormone analogs: synthesis and in vivo characteristics of radiopeptides with high in vitro activity.
Bapst JP; Froidevaux S; Calame M; Tanner H; Eberle AN
J Recept Signal Transduct Res; 2007; 27(5-6):383-409. PubMed ID: 18097939
[TBL] [Abstract][Full Text] [Related]
2. A gallium-labeled DOTA-alpha-melanocyte- stimulating hormone analog for PET imaging of melanoma metastases.
Froidevaux S; Calame-Christe M; Schuhmacher J; Tanner H; Saffrich R; Henze M; Eberle AN
J Nucl Med; 2004 Jan; 45(1):116-23. PubMed ID: 14734683
[TBL] [Abstract][Full Text] [Related]
3. DOTA alpha-melanocyte-stimulating hormone analogues for imaging metastatic melanoma lesions.
Froidevaux S; Calame-Christe M; Sumanovski L; Tanner H; Eberle AN
Ann N Y Acad Sci; 2003 Jun; 994():378-83. PubMed ID: 12851339
[TBL] [Abstract][Full Text] [Related]
4. Melanoma targeting with DOTA-alpha-melanocyte-stimulating hormone analogs: structural parameters affecting tumor uptake and kidney uptake.
Froidevaux S; Calame-Christe M; Tanner H; Eberle AN
J Nucl Med; 2005 May; 46(5):887-95. PubMed ID: 15872364
[TBL] [Abstract][Full Text] [Related]
5. Reduction of the ring size of radiolabeled lactam bridge-cyclized alpha-MSH peptide, resulting in enhanced melanoma uptake.
Guo H; Yang J; Gallazzi F; Miao Y
J Nucl Med; 2010 Mar; 51(3):418-26. PubMed ID: 20150256
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of melanocortin-1 receptor (MC1-R) specific
Nagy G; Dénes N; Kis A; Szabó JP; Berényi E; Garai I; Bai P; Hajdu I; Szikra D; Trencsényi G
Eur J Pharm Sci; 2017 Aug; 106():336-344. PubMed ID: 28625749
[TBL] [Abstract][Full Text] [Related]
7. Effect of DOTA position on melanoma targeting and pharmacokinetic properties of 111In-labeled lactam bridge-cyclized alpha-melanocyte stimulating hormone peptide.
Guo H; Yang J; Gallazzi F; Prossnitz ER; Sklar LA; Miao Y
Bioconjug Chem; 2009 Nov; 20(11):2162-8. PubMed ID: 19817405
[TBL] [Abstract][Full Text] [Related]
8. A novel DOTA-alpha-melanocyte-stimulating hormone analog for metastatic melanoma diagnosis.
Froidevaux S; Calame-Christe M; Tanner H; Sumanovski L; Eberle AN
J Nucl Med; 2002 Dec; 43(12):1699-706. PubMed ID: 12468522
[TBL] [Abstract][Full Text] [Related]
9. 64Cu-labeled alpha-melanocyte-stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression.
Cheng Z; Xiong Z; Subbarayan M; Chen X; Gambhir SS
Bioconjug Chem; 2007; 18(3):765-72. PubMed ID: 17348700
[TBL] [Abstract][Full Text] [Related]
10. Glycosylated DOTA-alpha-melanocyte-stimulating hormone analogues for melanoma targeting: influence of the site of glycosylation on in vivo biodistribution.
Bapst JP; Calame M; Tanner H; Eberle AN
Bioconjug Chem; 2009 May; 20(5):984-93. PubMed ID: 19388674
[TBL] [Abstract][Full Text] [Related]
11. Small-animal PET of melanocortin 1 receptor expression using a 18F-labeled alpha-melanocyte-stimulating hormone analog.
Cheng Z; Zhang L; Graves E; Xiong Z; Dandekar M; Chen X; Gambhir SS
J Nucl Med; 2007 Jun; 48(6):987-94. PubMed ID: 17504880
[TBL] [Abstract][Full Text] [Related]
12. [111In]-DTPA-labeled analogues of alpha-melanocyte-stimulating hormone for melanoma targeting: receptor binding in vitro and in vivo.
Bagutti C; Stolz B; Albert R; Bruns C; Pless J; Eberle AN
Int J Cancer; 1994 Sep; 58(5):749-55. PubMed ID: 8077062
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a novel Arg-Gly-Asp-conjugated α-melanocyte stimulating hormone hybrid peptide for potential melanoma therapy.
Yang J; Guo H; Gallazzi F; Berwick M; Padilla RS; Miao Y
Bioconjug Chem; 2009 Aug; 20(8):1634-42. PubMed ID: 19552406
[TBL] [Abstract][Full Text] [Related]
14. The pharmacological properties of 3-arm or 4-arm DOTA constructs for conjugation to α-melanocyte-stimulating hormone analogues for melanoma imaging.
Kobayashi M; Kato T; Washiyama K; Ihara M; Mizutani A; Nishi K; Flores LG; Nishii R; Kawai K
PLoS One; 2019; 14(3):e0213397. PubMed ID: 30901323
[TBL] [Abstract][Full Text] [Related]
15. Novel [
Qiao Z; Xu J; Gonzalez R; Miao Y
Mol Pharm; 2020 Sep; 17(9):3581-3588. PubMed ID: 32663011
[TBL] [Abstract][Full Text] [Related]
16. Receptor-Mediated Melanoma Targeting with Radiolabeled α-Melanocyte-Stimulating Hormone: Relevance of the Net Charge of the Ligand.
Bapst JP; Eberle AN
Front Endocrinol (Lausanne); 2017; 8():93. PubMed ID: 28491052
[TBL] [Abstract][Full Text] [Related]
17. Effects of the amino acid linkers on the melanoma-targeting and pharmacokinetic properties of 111In-labeled lactam bridge-cyclized alpha-MSH peptides.
Guo H; Yang J; Gallazzi F; Miao Y
J Nucl Med; 2011 Apr; 52(4):608-16. PubMed ID: 21421725
[TBL] [Abstract][Full Text] [Related]
18. Radioiodination of rhenium cyclized alpha-melanocyte-stimulating hormone resulting in enhanced radioactivity localization and retention in melanoma.
Cheng Z; Chen J; Quinn TP; Jurisson SS
Cancer Res; 2004 Feb; 64(4):1411-8. PubMed ID: 14973076
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
